Clinical trials: Neoplasms by Site
Non-small Cell Lung Cancer
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the effect on toxicity of the addition of CS 1008 to a platinum based chemotherapy regimen on the progression-free survival (PFS) in subjects with stage IIIB wet or stage IV NSCLC.
- Trial name
- NCT00991796
- Testing
- CS-1008, Paclitaxel, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Daiichi Sankyo
Solid Tumours
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
This is an open-label, multi-center, dose-finding Phase 1 study that will enroll subjects at least 18 years old with unresectable or metastatic melanoma and BRAF V600 mutations.
- Trial name
- NCT01767454
- Testing
- Dabrafenib, Trametinib, Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts…
- Trial name
- NCT06686394
- Testing
- Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 181 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have advanced or…
- Trial name
- NCT00004866
- Testing
- exatecan mesylate
- Where
- 6 sites in United States
- Sponsor
- Daiichi Sankyo
Breast Neoplasms
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group.
- Trial name
- NCT07173751
- Testing
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
- Where
- 224 sites in United States, Argentina and 17 more
- Volunteers
- 558 people
- Sponsor
- BioNTech SE
Metastatic Colorectal Cancer, Gastric Cancer
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03724851
- Testing
- TEW-7197
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- MedPacto, Inc.
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Small Cell Lung Cancer
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006…
- Trial name
- NCT07559929
- Testing
- DXC006, Toripalimab, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Human Mammary Carcinoma
A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
This is an open-label multicenter, phase 1-2 study. Following determination of the recommended AEG35156 dose in combination with weekly paclitaxel in the initial Phase 1 part of this study, additional patients will be enrolled in…
- Trial name
- NCT00558545
- Testing
- AEG35156
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Aegera Therapeutics
Renal Cell Carcinoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT03592472
- Testing
- Pazopanib, Abexinostat
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 413 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
- Trial name
- NCT04616196
- Testing
- NKTR-255, Cetuximab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Carcinoma, Non-Small-Cell Lung
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+)…
- Trial name
- NCT04075396
- Testing
- Lazertinib
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Cancer
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced…
- Trial name
- NCT00273546
- Testing
- XRP6976 (Docetaxel/Taxotere)
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 500 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer (NSCLC)
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio.
- Trial name
- INFORM (NCT00770588)
- Testing
- Gefitinib
- Where
- 14 sites in China
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
This single arm study will assess the efficacy and safety of a combination of Avastin and docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable breast cancer.
- Trial name
- NCT00559754
- Testing
- bevacizumab [Avastin], Docetaxel, Standard chemotherapy
- Where
- 6 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.
- Trial name
- NCT02117479
- Testing
- Ruxolitinib, Capecitabine
- Where
- 230 sites in United States, Australia and 10 more
- Volunteers
- 321 people
- Sponsor
- Incyte Corporation
NSCLC
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of…
- Trial name
- NCT06094296
- Testing
- BMS-986315, Nivolumab, Pemetrexed
- Where
- 8 sites in United States, Australia
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
NSCLC, Non-small Cell Lung Cancer
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with…
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- RASolve 308 (NCT07777822)
- Testing
- zoldonrasib, pembrolizumab, pemetrexed + cisplatin /carboplatin
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Revolution Medicines, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.